Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice

Clinical Cancer Research

Volumn 12, Issue 15, 2006, Pages 4695-4701

  Zhang, YuJian ^a   Xiang, Laiman ^a   Hassan, Raffit ^a   Paik, Chang H ^b   Carrasquillo, Jorge A ^b   Jang, Beom Su ^b   Le, Nhat ^b   Ho, Mitchell ^a   Pastan, Ira ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Laboratory of Biochemistry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; CYCLOPHOSPHAMIDE; IMMUNOTOXIN; IMMUNOTOXIN SS1P; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; EXPERIMENTAL MODEL; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; TUMOR; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MICE; MICE, NUDE; PACLITAXEL; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33748070220     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0346     Document Type: Article

References (30)

1. Reiter Y, Pastan I. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: bisulfide-stabilized Fv immunotoxins. Clin Cancer Res 1996;2:245-52.
2. Krietman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistance Hairy-cell leukemia. N Engl J Med 2001;345:241-7.
3. Pastan IH, Pai LH, Brinkmann U, Fitzgerald DJ. Recombinant toxins: new therapeutic agents for cancer. Ann N Y Acad Sci 1995;758:345-54.
4. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18:1622-36.
5. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42.
6. Hassan R, Bullock S, Kreitman RJ, Kindler HL, Pastan I. Targeted therapy of mesothelin expressing mesotheliomas (MM), ovarian cancer (OC) and pancreatic cancer (PC): results of phase I study of SS1 (dsFv)-PE38 (SS1P). Proc Am Soc Clin Oncol Annu Meet 2004;22:3035.
7. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999;1:241-63.
8. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13.
9. Leveque D, Wisniewski S, Jehl F. Pharmacokinetics of therapeutic monoclonal antibodies used in oncology. Anticancer Res 2005;25:2327-43.
10. Holden SA, Lan Y, Pardo AM, Wesolowski JS, Gillies SD. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. Clin Cancer Res 2001;7:2862-9.
11. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-9.
12. Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003;14:13-9.
13. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
14. Goto H, Yano S, Matsumori Y, Ogawa H, Blakey DC, Sone S. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin. Clin Cancer Res 2004;10:7671-6.
15. Zhang L, Yu D, Hicklin DJ, Hannay JA, Ellis LM, Pollock RE. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res 2002;62:2034-42.
16. Pastan I, Beers R, Bera T. Recombinant immunotoxins in the treatment of cancer. In: Lo BKD, ed. Methods in molecular biology. Antibody engineering: methods and procotols. Vol 248. Clifton (NJ): Humana Press; 2003. p. 503-18.
17. Bang S, Nagata S, Onda M, Kreitman RJ, Pastan I. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 2005;11:1545-50.
18. 125I-labeled antitac single-chain Fv recombinant immunotoxin. J Nucl Med 2000;41:755-62.
19. Tan M, Fang HB, Tian GL, Houghton PJ. Repeated-measures models with constrained parameters for incomplete data in tumour xenograft experiments. Stat Med 2004;24:109-19.
20. Griffon-Etienne G, Boucher Y, Breken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999; 59:3776-82.
21. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996;56:2112-5.
22. L'Azou B, Fernandez P, Bareille R, et al. In vitro endothelial cell susceptibility to xenobiotics: comparison of three cell types. Cell Biol Toxicol 2005;21:127-37.
23. Sato N, Hassan R, Axworthy DB, et al. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J Nucl Med 2005;46:1201-9.
24. 111In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers? Clin Cancer Res 2005;11:7158-63s.
25. Gillies SD, Lan Y, Lo KM, Super M, Wesolowski J. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors. Cancer Res 1999;59:2159-66.
26. Epstein AL, Mizokami MM, Li J, Hu P, Khawli LA. Identification of a protein fragment of interleukin 2 responsible for vasopermeability. J Natl Cancer Inst 2003;95:741-9.
27. 2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy. Clin Cancer Res 2005;11:3084-93.
28. Tisty TD. Stromal cells can contribute oncogenic signals. Semin Cancer Biol 2001;11:97-104.
29. Chan OTM, Yang LX. The immunological effects of taxanes. Cancer Immunol Immunother 2000;49:181-5.
30. Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 2006;4:61-70.